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INTRODUCTION
Opportunistic bacterial and fungal infections are major
complications after myeloablative hematopoietic stem cell
transplantation (HSCT). Although prophylaxis and treat-
ment strategies have been improved over the years, infec-
tions still contribute signiﬁcantly to morbidity and mortality
among HSCT recipients in the early posttransplantation
period [1-3]. Risk factors associated with bacterial and fun-
gal infections include severe and long-lasting neutropenia,
regimen-related toxicity (ie, mucositis), infection with
cytomegalovirus (CMV), and graft-versus-host disease
(GVHD) and its treatment with corticosteroids [3-6].
Over recent years, nonmyeloablative HSCT regimens
have been developed and explored for the treatment of
patients who are considered ineligible for myeloablative
HSCT because of medical contraindications or age [7-11].
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ABSTRACT
Infections contribute significantly to morbidity and mortality after myeloablative allogeneic hematopoietic stem cell
transplantation (HSCT). Whether recipients of nonmyeloablative HSCT have different posttransplantation infec-
tion risk was unknown. We therefore analyzed the incidence and risk of bacteremia during the first 100 days and of
fungal infection during the first 365 days posttransplantation for 56 consecutive patients with hematological malig-
nant disease who received nonmyeloablative HSCT (case patients). We compared the results with those among
112 control patients who received conventional myeloablative HSCT during the same years (January 1997–April
2000). Control patients were matched (2:1) for cytomegalovirus (CMV) risk group, HSC source, donor type, age,
and underlying disease. Most donors (93%) were HLA-matched and related. Case patients had shorter periods of
neutropenia (absolute neutrophil count, <100/mm3) than did control patients (median, 0 days; range, 0-11 versus
9 days; range, 4-25; P < .0001). This finding was associated with fewer episodes of bacteremia during the first 30 days
(9% versus 27%; P = .01) and a trend to fewer episodes of bacteremia during the first 100 days posttransplantation
(27% versus 41%, P = .07). Overall survival was significantly improved in case patients compared with control
patients (day 100, 93% versus 81%; P = .04). During the first year posttransplantation, invasive aspergillosis
occurred at a similar rate (case patients, 15%; control patients, 9%; P value not significant). Multivariate risk factor
analyses identified neutropenia and CMV disease as the major factors associated with bacteremia and aspergillosis,
respectively. We conclude that shorter periods of severe neutropenia in nonmyeloablative HSCT are associated with
decreased risk of early bacteremia, although risk of fungal infection late after HSCT persists. This risk is an impor-
tant consideration for the future development of preventive strategies.
KEY WORDS
Nonmyeloablative • Transplantation • Bacterial • Infection • Fungal
Biology of Blood and Marrow Transplantation 8:512-520 (2002)
© 2002 American Society for Blood and Marrow Transplantation
#02-053-Junghanss
ASBMT
P.A.M. is now with the University of Colorado, Denver, Colorado.
Bacterial and Fungal Infections after Nonmyeloablative Transplantation
513B B & M T
The toxicity profiles vary between regimens, especially in
the degree of myeloablation, but are generally considered to
be lower than those of conventional HSCT [8,12]. The
nonmyeloablative HSCT regimen that was developed in
Seattle is based on low-dose (2 Gy) total body irradiation
(TBI), with or without fludarabine, for pretransplantation
conditioning followed by cyclosporine (CSP) and mycophe-
nolate mofetil (MMF) in the posttransplantation period [8].
This regimen provides pre- and posttransplantation
immunosuppression that allows engraftment and initial
establishment of mixed donor-host hematopoietic chimerism.
The effects of this regimen on myelopoiesis, eg, neutrophils,
are moderate, and severe neutropenia is rare [8]. In addition,
damage to the mucosal barriers of the gastrointestinal tract
is mild with the regimen, thus the possibility of hematoge-
nous spread of oral and gastrointestinal ﬂora is allayed. On
the basis of these findings, we hypothesized that among
recipients of nonmyeloablative HSCT, the incidence of
early posttransplantation bacterial and fungal infections
would be lower than the incidence among patients given
conventional myeloablative HSCT.
To test our hypothesis, we performed a matched-pair con-
trol study to compare the results among the ﬁrst 56 consecu-
tive patients who received nonmyeloablative HSCT at our
institutions with the results among 112 concurrently treated
patients who received myeloablative allogeneic HSCT. We
analyzed bacteremia during the ﬁrst 100 days and fungal infec-
tion during the ﬁrst 365 days after transplantation.
PATIENTS AND METHODS
This retrospective analysis was approved by the institu-
tional review boards of the Fred Hutchinson Cancer Research
Center and the Veterans Affairs Medical Center in Seattle.
Records of the cases of 56 consecutive patients who had
received nonmyeloablative allogeneic HSCT (case patients)
between December 1997 and April 2000 were analyzed.
Fifty-ﬁve case patients had hematological malignant disease,
and 1 case patient had renal cell carcinoma. Patients were
treated either at the Fred Hutchinson Cancer Research
Center (FHCRC) or at the Veterans Affairs Medical Center,
both in Seattle, Washington. These 2 institutions had simi-
lar surveillance and prevention strategies for infection. Each
case patient was matched to 2 control patients.
The control patients were identiﬁed among 854 patients
who received myeloablative HSCT at FHCRC from January
1997 to April 2000. Matching was attempted for the follow-
ing criteria: CMV risk group (low, intermediate, high), donor
type (HLA-matched related donor, HLA-matched unrelated
donor), HSC source (peripheral blood stem cells [PBSC]
versus bone marrow [BM]), age at transplantation (<20, 20-40,
>40 years), and diagnosis (low risk versus high risk).
Classiﬁcation of CMV risk group was based on previous
results of myeloablative transplantation [13]: low risk (donor
and recipient serologically negative), intermediate risk (donor
serologically positive and recipient negative), and high risk
(recipient positive and donor negative or positive). The strati-
ﬁcation based on underlying disease was as follows. High risk
was defined as active de novo or relapsed acute myeloid
leukemia, myelodysplastic syndrome (MDS) (refractory ane-
mia with excess of blasts [RAEB] or excess of blasts in trans-
formation [RAEB-T]), acute lymphocytic leukemia [ALL],
chronic lymphocytic leukemia (CLL), non-Hodgkin’s lym-
phoma (NHL), Hodgkin’s disease (HD), multiple myeloma
(MM) regardless of status, renal cell carcinoma, accelerated
chronic myeloid leukemia (CML), or blast crisis of CML.
Low risk was deﬁned as aplastic anemia, any of the above-
named diseases with unknown disease status or in remission
except for MM, CML chronic phase and MDS (refractory
anemia [RA], RA with ringed sideroblast [RARS]) [14].
One hundred percent matching was achieved for CMV
risk group, donor-recipient HLA matching, and HSC
source; 86% for age (>40 years, 89% of case patients versus
78% of control patients; P = .07); and 63% for underlying
disease (high risk, 68% of case patients versus 44% of con-
trol patients; P = .003). Most patients in both groups were
white (case patients, 48 of 56 [86%]; control patients, 97 of
112 [87%]).
Preparative Regimens
Case patients received low-dose TBI (2 Gy, day 0) fol-
lowed by CSP and MMF posttransplantation [8]. This regi-
men was modiﬁed after the ﬁrst 38 patients by the addition
of ﬂudarabine 30 mg/m2 body surface area per day on days
–4 to –2. Control patients received the conditioning regi-
mens shown in Table 1, most commonly cyclophosphamide
(60 mg/kg per day for 2 consecutive days) followed by TBI
(12 Gy) or busulfan (4 mg/kg per day for 4 consecutive days)
followed by cyclophosphamide (60 mg/kg per day for 2 con-
secutive days) [15].
Prophylaxis against Graft-versus-Host Disease
Case patients were assigned to receive CSP, 6.25 mg/kg
by mouth twice a day (PO BID) from day –1 to day +35 for
related-donor transplantation and from day –1 to day +100
for unrelated-donor transplantation. CSP was then tapered,
so that the last dose was scheduled to be given on days +56
(related donors) and +180 (unrelated donors). Tapering
schedules were modiﬁed at the discretion of the attending
physician if active GVHD was present. MMF was given at a
dosage of 15 mg/kg PO BID from days 0 to +27 for related-
donor transplantation and through day +40 with subsequent
taper to day +96 for unrelated-donor transplantation [16].
Control patients received one of several GVHD prophylaxis
regimens during the study period, most commonly the com-
bination of CSP and methotrexate (MTX) [17]. CSP was
given at a dosage of 1.5 mg/kg intravenously (IV) BID or
6.25 mg/kg PO BID on days –1 to + 60 and then tapered
until day +180. MTX was scheduled to be administered IV
at a dosage of 15 mg/m2 of body surface area on day +1 and
10 mg/m2 on days +3, +6, and +11.
Graft-versus-Host Disease and Treatment
Diagnosis and clinical grading of acute GVHD were
performed according to established criteria [18]. GVHD
data were available for 47 case patients and 110 control
patients. The distribution within case patients and control
patients was similar (P = .74): grade 0, 30%/26%; grade 1,
0/5%; grade 2, 57%/53%; grade 3, 11%/13%; and grade 4,
2%/4%. Grouping the data to compare grades 0 through 2
with grades 3 and 4 did not show a significant difference
between case patients (87% versus 13%) and control
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patients (84% versus 16%, P = .57). Grouping the data to
compare grades 0 and 1 with grades 2 through 4 also did not
show a significant difference between case patients (30%
versus 70%) and control patients (31% versus 69%, P = .89).
The median day of onset was later for the case patients (day
48, range 7-109) than for the control patients (day 20, range
6-52; P < .0001). GVHD was usually treated with pred-
nisolone and/or restart of CSP if the drug had been tapered.
Infection Prophylaxis, Monitoring, and Diagnosis
All patients received prophylactic antibiotics (ceftazidime
or ciproﬂoxacin) when absolute neutrophil count (ANC) was
<0.5 × 109/L. Patients who had positive serologic results for
herpes simplex virus (HSV) received prophylactic low-dose
acyclovir from day –5 to day +30 or until resolution of
mucositis, whichever occurred earlier [19]. Fluconazole
(400 mg/d) was given to all patients from the start of condi-
tioning to day +75 after transplantation [20]. Prophylaxis
against Pneumocystis carinii infection was performed with
trimethoprim-sulfamethoxazole as ﬁrst-line treatment, and
dapsone (50 mg BID) was used as second-line treatment [21].
Patients were monitored through day 365 after transplantation
with weekly CMV antigenemia testing for the development
of CMV infection and disease [14]. Positive antigenemia,
defined as more than 1 cell per 150,000 cells, was treated
with ganciclovir twice daily for 2 weeks followed by daily
administration of ganciclovir until day 100 or for 3 weeks
[14]. CMV disease was identified independently. Patients
with persistent fever while they were taking prophylactic
antibiotics received additional agents (vancomycin, amino-
glycosides, and/ or amphotericin B) as clinically indicated.
Physical examination, chest x-rays, and blood cultures were
performed to identify any source of infection. Invasive pro-
cedures, including bronchoalveolar lavage and biopsy, were
performed when clinically indicated. All specimens were sub-
mitted for bacterial and fungal cultures, which were per-
formed according to standard methods.
Definitions
Previously described deﬁnitions of infection were used in
this study [19,22]. The day of onset of an infection was
deﬁned as the day when the diagnostic test was performed.
Bacteremia and candidemia were diagnosed on the basis of
positive results of blood cultures. Bacteremia was considered
recurrent if the same organism was recovered in culture,
except if positive results of cultures were separated by more
than 30 days. Survival was evaluated per episode of bac-
teremia. Invasive aspergillosis was classified as proven or
probable according to standardized criteria [22]. Briefly,
infection was considered proven if a biopsy specimen
revealed consistent histopathologic findings or growth of
Aspergillus organisms. Probable invasive aspergillosis was
deﬁned by a positive culture result of bronchoalveolar lavage.
Statistical Analysis
For comparison of characteristics of case patients with
control patients, summary statistics, including frequency
counts and percentages for categorical variables, as well as
medians and ranges for age at transplantation, were calcu-
lated. Comparisons from 2 × 2 tables were made with χ2 and
Fisher exact tests. Median time until onset of an event as
well as days and levels of ANC nadirs were compared with
the Wilcoxon rank sum test. Cumulative incidence curves
up to 100 days posttransplantation were produced for bac-
teremia. Because invasive aspergillosis frequently occurs
after day 100 [23], these curves were extended to 365 days.
Univariate and multivariate Cox regression models were
used to analyze the inﬂuence of selected variables on the risk
of infection. Times to events were the outcomes for the Cox
regression models with censoring at death, subsequent trans-
plantation, or the end of follow-up. Acute GVHD and CMV
disease were entered as time-dependent covariates. Follow-
up times in the model used to examine early infectious events
were censored at day 100. Variables for the multivariate
models were selected with backward stepwise elimination
with significance greater than P = .05 as the criterion for
Table 1. HSCT Patient Characteristics*
Nonmyeloablative Myeloablative
Patient characteristics (n = 56), n (%) (n = 112), n (%)
No. of women 14 (25) 42 (38) 
Disease
ALL 1 (2) 17 (15)
ANL 8 (14) 25 (22)
CLL 8 (14) 2 (2)
CML 3 (5) 19 (17)
HD 6 (11) 0 (0)
MDS 6 (11) 28 (25)
MM 13 (23) 6 (5)
NHL 10 (18) 14 (13)
Other 1 (2)† 1 (1)‡
Diagnosis group
Low risk 18 (32) 63 (56)
High risk 38 (68) 49 (44)
Median age at transplantation, y 54 46
Age at transplantation <20 y 1 (2) 4 (4)
Age at transplantation 20-40 y 5 (9) 21 (19)
Age at transplantation >40 y 50 (89) 87 (78)
CMV risk group
Low 12 (21) 24 (21)
Intermediate 10 (18) 20 (18)
High 34 (61) 68 (61)
Donor
HLA-matched related donor 52 (93) 104 (93)
HLA-matched unrelated donor 4 (7) 8 (7)
Stem cell source
BM 2 (4) 4 (4)
PBSC 54 (96) 108 (96)
Conditioning
TBI (2 Gy) 38 (68)
TBI (2 Gy) + fludarabine 18 (32)
Busulfan/cyclophosphamide 44 (39)
Cyclophosphamide/TBI (>10 Gy) 43 (38)
Busulfan/TBI (>10 Gy) 15 (13)
Other 10 (9)
GVHD prophylaxis
CSP + MMF 56 (100) 5 (4)
CSP + methotrexate 101 (90)
CSP 3 (3)
Other 3 (3)
*ANL indicates acute nonlymphocytic leukemia.
†Renal cell carcinoma.
‡Aplastic anemia.
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removal from the models. Conﬁdence limits were calculated
with the assumption of normality of parameter estimates,
and P values were calculated with the likelihood ratio test.
One-hundred-day survival after bacteremia and 1-year
survival after aspergillosis were compared between case
patients and control patients with Kaplan-Meier curves and
the log-rank test. Survival was calculated after ﬁrst episodes
for patients who had multiple episodes of bacteremia.
RESULTS
The median follow-up period was 12.7 months (range,
1.1-28.4 months) for case patients and 12.7 months (range,
0.1-48.1 months) for control patients. The overall 30- and
100-day survivals among case patients were significantly
better than were those among control patients (100% versus
90%, P = .02; 93% versus 81%, P =. 04) (Figure 1).
Case patients had signiﬁcantly higher median ANC nadirs
than did control patients (310/mm3 [range, 0-3000 ANC]
versus 0/mm3 [range, 0-102 ANC], P < .0001) (Figure 2).
The median day of ANC nadir was also signiﬁcantly differ-
ent between case and control patients (day 16 [range, day 6-91]
versus day 7 [range, day 0 to 12], P < .0001). The median
number of days that ANC was <500/mm3 and <100/mm3
was higher among case patients (14 and 9 days, respectively)
than among control patients (2 and 0 days, respectively,
P < .0001).
Bacterial Infections
During the ﬁrst 100 days posttransplantation, 24 episodes
of bacteremia occurred in 15 case patients, and 83 episodes of
bacteremia occurred in 46 control patients. Consequently,
the cumulative incidence of bacteremia tended to be lower
among case patients than among control patients during that
time period (27% versus 41%, P = .07) and was signifi-
cantly lower among case patients during the first 30 days
(9% versus 27%, P = .01) (Figure 3). Bacteremia tended to
occur later in the case patients than in the control patients
(median day 44 [range, day 0-95] versus median day 17
[range, day 1-96], P = .07). The median ANC at onset of bac-
teremia was 2730/mm3 in the case patients and 1012/mm3 in
the control patients (P = .12).
Organisms that caused bacteremia are shown in Table 2.
No signiﬁcant difference was observed between the number
of episodes of bacteremia caused by Gram-positive and the
number caused by Gram-negative organisms in case patients
compared with control patients (P = 1.00). Because the
overall cumulative incidence and timing of bacteremia were
different between case patients and control patients, we ana-
lyzed separately infections typically associated with the pres-
ence of intravascular catheters (“line-related infections”
caused by Staphylococcus aureus, coagulase-negative staphylo-
cocci, unspecified staphylococci, and Corynebacteria and
Micrococcus organisms) and mucositis (Gram-negative bacte-
ria and streptococci including Enterococcus organisms). The
cumulative incidences of line-related infections were similar
in the two groups during the ﬁrst 30 days (5 case patients
[9%] versus 15 control patients [13%], P = .40) and 100 days
(11 case patients [20%] versus 30 control patients [27%],
P = .31) (Figure 3). However, case patients had signiﬁcantly
fewer episodes of mucositis-associated infection than did
control patients during the ﬁrst 30 days (1 case patient [2%]
versus 16 control patients [14%], P = .01) and a trend to
fewer mucositis-associated infections during the first
100 days (7 case patients [13%] versus 27 control patients
[24%], P = .08) (Figure 3).
Fungal Infections
Four patients (3 control patients and 1 case patient) had
documented fungal infections before transplantation and
were therefore excluded from the cumulative incidence and
multivariate risk factor analyses. One control patient had
documented hepatosplenic candidiasis, 1 control patient
had invasive sinus infection with Zygomycetes, and
2 patients (1 case and 1 control patient) had invasive pul-
monary aspergillosis pretransplantation. The control
patient with invasive aspergillosis died of progressive dis-
ease on day 3 after transplantation, and the case patient
Figure 1. Overall survival. The probability of overall survival is shown
for all case and control patients for up to 100 days posttransplantation.
Case patients had better 30-day (P = .02) and 100-day (P = .04) survival.
Figure 2. Median absolute neutrophil count (ANC) after hemato-
poietic stem cell transplantation. The median ANC nadir posttrans-
plantation was signiﬁcantly lower among control patients than it was
among case patients (P < .001).
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with invasive aspergillosis had a stable course and is alive at
this writing. The other 2 control patients died of other
causes on days 200 and 334 after HSCT.
Within the first year posttransplantation, proven and
probable invasive aspergillosis occurred at similar rates in
case patients (n = 8 [15%]; 4 proven, 4 probable) and con-
trol patients (n = 10 [9%]; 6 proven, 4 probable; P = .30)
(Figure 4). The median day of onset was later among case
patients than among control patients (median day 147
Figure 3. Cumulative incidence of bacteremia. The cumulative inci-
dence of bacteremia during the first 100 days posttransplantation are
displayed. Case patients had significantly fewer episodes of bac-
teremia during the first 30 days posttransplantation (P = .01) and a
trend to fewer episodes of bacteremia at day 100 (P = .07) (A). Line-
related bacteremia (associated with the presence of an intravascular
catheter) occurred at similar rates in case and control patients during
the first 30 days posttransplantation (P = .40) and during the first
100 days (P = .31) (B). The number of episodes of mucositis-associated
infection was significantly lower among case patients than it was
among control patients during the first 30 days posttransplantation
(P = .01) and tended to be lower during the first 100 days posttrans-
plantation (P = .08) (C).
Figure 4. Cumulative incidence of invasive aspergillosis. The cumula-
tive incidences of proven and probable invasive aspergillosis during the
first year posttransplantation are displayed. Invasive aspergillosis
occurred at similar rates among case and control patients (P = .30).
Table 2. Species That Caused Bacteremia during the First 100 Days 
Posttransplantation
Nonmyeloablative, Myeloablative,
Characteristics n (%) n (%) P
Total episodes 24 (100) 83 (100)
Gram negative 3 (13) 13 (16) 1.000
Acinetobacter species 0 (0) 1 (1)
Enterobacter species 1 (4) 2 (2)
Escherichia coli 0 (0) 1 (1)
Klebsiella species 1 (4) 2 (2)
Pseudomonas species 0 (0) 6 (7)
Proteus mirabilis 0 (0) 1 (1)
Serratia marcescens 1 (4) 0 (0)
Gram positive 21 (88) 70 (84)
Gram-positive bacilli 1 (4) 3 (4)
Bifidobacterium 1 (4) 0 (0)
Corynebacterium species 4 (17) 4 (5)
Enterococcus faecalis 0 (0) 9 (11)
Lactobacillus 0 (0) 1 (1)
Leuconostoc 0 (0) 1 (1)
Micrococcus 0 (0) 4 (5)
Staphylococcus species, 0 (0) 2 (2)
not otherwise specified
Coagulase-negative 10 (42) 30 (36) 
staphylococci
Staphylococcus aureus 1 (4) 1 (1)
Streptococcus species 4 (17) 15 (18)
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[range, day 35-286] versus median day 78 [range, day 44-
184]), although this difference was not statistically signifi-
cant (P = .17).
The incidence of candidemia was low in both case
patients and control patients (n = 4 [7%] and n = 1 [1%], P =
.04). Species that caused infections in case patients were
Candida glabrata (n = 3) and Candida parapsilosis (n = 1). One
control patient developed Candida albicans candidemia
despite amphotericin B therapy in the setting of severe
mucositis and concomitant bacteremia. The median day of
onset of candidemia was day 123 (range, day 73-178) for the
case patients and day 25 (1 patient) for the control patients
(P = .35). All episodes of candidemia in the case patients
occurred after ﬂuconazole prophylaxis was discontinued.
Univariate and Multivariate Risk Factor Analysis
Multivariate analyses were performed to identify risk
factors for bacteremia (Table 3). Patients who received non-
myeloablative HSCT had a significantly decreased risk of
bacteremia during the first 100 days posttransplantation.
Patients who received HSCT from unrelated donors,
patients who belonged to the high-risk group (on the basis
of disease and stage), and patients who had GVHD (grade
>1) had signiﬁcantly increased risk of bacteremia. When we
restricted the multivariate analyses to the ﬁrst 30 days post-
transplantation, ANC <100/mm3 for >10 days was associ-
ated with increased risk of bacteremia (relative risk [RR],
3.18; CI, 1.61-6.29; P = .001).
In a multivariate analysis of risk of invasive aspergillosis
with the variables outlined in Table 3, the signiﬁcant factors
identified during the first year were CMV disease (RR,
20.93; CI, 6.7-65.42; P < .0001), high-risk group (on the
basis of disease and stage; RR, 3.0; CI, 0.99-9.07), and age
greater than 40 years (RR, 4.34; CI, 0.86-22.00). In univari-
ate analysis, acute GVHD grade ≥2 was identiﬁed as a risk
factor for invasive aspergillosis (RR, 3.77; CI, 0.86-16.53;
P = .04), but this variable was no longer signiﬁcant in multi-
variate analyses. This was the last factor removed from the
model. Our ability to detect important associations with
GVHD may be limited by the low number of aspergillosis
diagnoses (n = 18). More severe GVHD (grade ≥3) also was
not identiﬁed as a signiﬁcant risk for invasive aspergillosis in
multivariate analyses (data not shown).
Survival after Infection
The 30-day survival after bacteremia tended to be better
among the case patients than among the control patients
(100% versus 83%, P = .09) (Figure 5). This trend persisted
when 100-day survival after bacteremia was analyzed (87%
versus 63%, P = .09). The 1-year survival after diagnosis of
aspergillosis also tended to be better among case patients
than among control patients (63% versus 30%, P = .22)
(Figure 5). The median duration of survival after candidemia
Table 3. Univariate and Multivariate Analyses of Risk Factors for Bacteremia during the First 100 Days*
Risk Factor Univariate RR (95% CI) P Adjusted RR (95% CI) P
Nonmyeloablative HSCT versus myeloablative HSCT 0.54 (0.30-0.97) .03 0.50 (0.26-0.95) .03
PBSC versus BM 0.47 (0.17-1.30) .19
Matched unrelated versus matched related 2.30 (1.09-4.87) .05 2.82 (1.24-6.44) .02
High-risk diagnosis versus low-risk diagnosis 1.27 (0.77-2.11) .35 1.87 (1.06-3.28) .03
Age >40 y versus other 0.82 (0.44-1.51) .53
CMV disease versus other 0.83 (0.11-6.08) .85
Acute GVHD grade >1 versus grade 0 and 1† 2.56 (1.32-4.97) .005 2.13 (1.08-4.20) .03
ANC <100/mm3 for >10 d versus shorter neutropenia 1.95 (1.12-3.39) .03
ANC <500/mm3 for >10 d versus shorter neutropenia 1.74 (0.98-3.08) .05
*RR indicates relative risk.
†Acute GVHD grade >2 was signiﬁcant in univariate and multivariate analyses.
Figure 5. Survival after infection. Probability of survival 100 days after
bacteremia (A) and 1 year after invasive aspergillosis (B) (proven and
probable) for case and control patients.
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did not differ between case and control patients (P = .35),
but the number of patients in this analysis was small.
DISCUSSION
Nonmyeloablative HSCT is, by deﬁnition, less myelo-
suppressive and associated with less gastrointestinal toxicity
[24] than is conventional HSCT. Whether this characteris-
tic would lead to a reduction of episodes of posttransplanta-
tion infection was unknown. Our matched-pair analyses
addressed this question, and the results suggest that
decreased myelosuppression and gastrointestinal mucositis
are associated with decreased risk of bacteremia. However,
late CMV disease is associated with persistent risk of inva-
sive fungal infection.
Previous studies have documented that the incidence of
bacteremia ranges from 24% to 55% after autologous or
allogeneic HSCT [3,25-27]. Results also have shown that
increased risk is notable among patients who have high-risk
underlying diagnoses and among recipients of grafts from
unrelated donors [3,28]. Results among current recipients of
myeloablative HSCT have conﬁrmed these ﬁndings. Com-
paratively, recipients of nonmyeloablative transplants had a
decreased risk of bacteremia, especially during the first
30 days. Results of detailed analyses of myelosuppression
and microbial epidemiology suggest that protection against
infection was primarily associated with shorter periods of
neutropenia and less severe gastrointestinal mucositis.
Severe and protracted neutropenia is associated with
increased risk of early posttransplantation infection [4].
However, recipients of nonmyeloablative HSCT in our
study had short and moderate neutropenia. This finding
compares favorably with results reported with other non-
myeloablative HSCT conditioning regimens. Childs et al.
investigated engraftment kinetics in 15 patients after non-
myeloablative HSCT for hematological malignant disease
or solid tumors in which cyclophosphamide and ﬂudarabine
were used for pretransplantation conditioning [29]. All
patients in that study developed neutropenia <100/mm3,
and the median time to neutrophil recovery >500/mm3 was
11 days (range, 9-15 days) posttransplantation. Another
study included 26 patients with hematological diseases who
received nonmyeloablative HSCT after pretransplantation
conditioning with ﬂudarabine, antithymocyte globulin, and
busulfan [10]. Sixty-six percent of the patients in the study
developed neutropenia <100/mm3 for a median of 4 days
(range, 0-20 days).
Another factor that likely contributed to the low inci-
dence of bacteremia is the reduced gastrointestinal toxicity
of the nonmyeloablative conditioning regimen, which
decreases the probability of mucosal invasion by oral and
gastrointestinal flora. Although no direct measures of
mucositis were available for all patients [24], our data
showed that recipients of nonmyeloablative HSCT had
significantly fewer infections caused by gastrointestinal
organisms such as Enterococcus species and Escherichia coli.
This ﬁnding underlines the importance of mucositis in the
pathogenesis of early posttransplantation infections and
indicates that despite better prevention of Gram-negative
infections with effective antibiotics [25,30,31], reduction in
the incidence and severity of mucositis continues to be a
worthy goal. Line-related infections occurred at similar
rates among case patients and control patients; this ﬁnding
demonstrated the persistent infection risk associated with
the presence of indwelling intravascular devices [32].
Aspergillus infections in HSCT recipients may occur dur-
ing the neutropenic phase following HSCT or later during
immunosuppression associated with GVHD or its treatment
[23,33-35]. In the current study, preengraftment aspergillosis
was rare in both case and control patients; this finding
demonstrated the increasingly important “late” character of
this infection. Results of risk factor analysis indicated that
important variables predictive of late aspergillosis included
CMV disease, as has recently been described in a large
cohort of recipients of myeloablative transplants [36,37]. Our
prior analyses of CMV infections within this same cohort
showed that recipients of nonmyeloablative transplants have
a later onset of CMV disease than do recipients of myeloab-
lative conditioning (median onset, 130 days versus 52 days)
[14]. One hundred days after HSCT, the incidence of CMV
infection was 19.1% among control patients and 5.9%
among case patients; however by 1 year, the incidence among
control and case patients was 25.0% and 24.3%, respectively
[14]. The observation that recipients of nonmyeloablative
HSCT tended toward a later median day of onset of
aspergillosis may be explained by a combination of variable
risks, including shorter periods of neutropenia, delayed onset
of GVHD, and late infection with CMV.
Recipients of nonmyeloablative transplants tended to
have better survival after both bacteremia and invasive
aspergillosis than did recipients of myeloablative HSCT.
Although improved survival after bacteremia may be related
to different causative organisms or ANC levels at the time
of infection, the variables predicting survival in patients with
aspergillosis are unknown. The certainty of diagnosis and
therapeutic regimens were equivalent (data not shown). One
possible explanation may be that the variable risks lead to
more episodes of extrapulmonary dissemination among
recipients of myeloablative transplants. Risks specific for
aspergillosis and predictors of outcome should be identiﬁed
in large prospective studies.
None of the patients in this study developed candidemia
while receiving ﬂuconazole. All patients had either ﬁnished
ﬂuconazole prophylaxis or were receiving amphotericin B in
the setting of severe mucositis when candidemia occurred.
This ﬁnding is consistent with the results of a large placebo-
controlled study that showed that fluconazole prophylaxis
for 75 days posttransplantation improves survival by pro-
tecting against candidiasis [1,20]. The continued risk of can-
didemia among recipients of nonmyeloablative HSCT may
be associated with the presence of gastrointestinal GVHD,
use of intravascular devices, or the later development of
CMV disease, all factors shown to impact risk of candidiasis
in prior studies [6]. These results suggest that protracted
risks for fungal infections may warrant prolonged prophy-
laxis in recipients of nonmyeloablative HSCT.
Our data demonstrate that nonmyeloablative HSCT
resulted in less myelosuppression and gastrointestinal toxic-
ity than did myeloablative transplantation; this characteristic
likely led to the lower incidence bacterial infections in the
early posttransplantation period and improved 100-day sur-
vival. The necessity for antibacterial prophylaxis should be
Bacterial and Fungal Infections after Nonmyeloablative Transplantation
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reevaluated. Persistent risks for late invasive fungal infec-
tions warrant efforts to develop preventive strategies.
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